Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-03-29
DOI
10.3389/fimmu.2021.616837
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
- (2020) Paola Ciciola et al. Journal of Clinical Medicine
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia
- (2020) Patricia E. de Almeida et al. Cancer Immunology Research
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
- (2019) Yosuke Togashi et al. Nature Reviews Clinical Oncology
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
- (2019) Shuang Qin et al. Journal of Hematology & Oncology
- A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
- (2019) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Limitations of Anti-Angiogenic Treatment of Tumors
- (2019) Domenico Ribatti et al. Translational Oncology
- VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers
- (2019) Chang Gon Kim et al. Science Immunology
- The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models
- (2018) Heinz Läubli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
- (2018) Yoshiro Itatani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
- (2018) Marco B. Schaaf et al. Cell Death & Disease
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma
- (2018) Courtney S. Malo et al. Frontiers in Oncology
- Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
- (2018) Yasuko Tada et al. Journal for ImmunoTherapy of Cancer
- OA11.07 Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer
- (2017) Sha Zhao et al. Journal of Thoracic Oncology
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis
- (2017) Lejia Sun et al. Oncotarget
- Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
- (2016) Naoki Horikawa et al. CLINICAL CANCER RESEARCH
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
- (2016) Yu-Ling Li et al. Cancer Biology & Medicine
- Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia
- (2015) Muhammad Zaeem Noman et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation
- (2015) Hua Huang et al. FASEB JOURNAL
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model
- (2015) Stephanie Du Four et al. OncoImmunology
- Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation
- (2014) Huaqin Yuan et al. BIOMEDICINE & PHARMACOTHERAPY
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Control of the Immune Response by Pro-Angiogenic Factors
- (2014) Thibault Voron et al. Frontiers in Oncology
- Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
- (2013) Mei-Ling Chen et al. INTERNATIONAL JOURNAL OF CANCER
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
- (2013) Magali Terme et al. OncoImmunology
- VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
- (2012) N G Gavalas et al. BRITISH JOURNAL OF CANCER
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma
- (2012) Hidenari Nagai et al. Clinical & Developmental Immunology
- Intratumoral FOXP3+VEGFR2+ regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer
- (2012) Hiroyuki Suzuki et al. CLINICAL IMMUNOLOGY
- Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages
- (2012) Nina Linde et al. JOURNAL OF PATHOLOGY
- Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
- (2012) Salem Chouaib et al. Frontiers in Immunology
- Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma
- (2011) Antonia Busse et al. EUROPEAN JOURNAL OF CANCER
- VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2
- (2011) Apostolos C. Ziogas et al. INTERNATIONAL JOURNAL OF CANCER
- Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
- (2011) Mengde Cao et al. LABORATORY INVESTIGATION
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
- (2011) M. Manzoni et al. ONCOLOGY
- Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
- (2010) V Goede et al. BRITISH JOURNAL OF CANCER
- Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects
- (2010) M. Kujawski et al. CANCER RESEARCH
- Combined treatment with Bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients
- (2010) Nikolaos Tsavaris et al. INVESTIGATIONAL NEW DRUGS
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
- (2010) Olivier Adotevi et al. JOURNAL OF IMMUNOTHERAPY
- Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer
- (2009) P.-Y. Pan et al. CANCER RESEARCH
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
- (2009) H. Xin et al. CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- VEGFR2 is selectively expressed by FOXP3high CD4+ Treg
- (2009) Hiroyuki Suzuki et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutting Edge: Vascular Endothelial Growth Factor-Mediated Signaling in Human CD45RO+ CD4+ T Cells Promotes Akt and ERK Activation and Costimulates IFN- Production
- (2009) A. Basu et al. JOURNAL OF IMMUNOLOGY
- Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells
- (2008) P. Serafini et al. CANCER RESEARCH
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
- Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells
- (2008) Ilaria Marigo et al. IMMUNOLOGICAL REVIEWS
- Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation
- (2008) W Zhao et al. LEUKEMIA
- Vascular normalization in Rgs5-deficient tumours promotes immune destruction
- (2008) Juliana Hamzah et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation